摘要
目的研究吲达帕胺联合苯磺酸左旋氨氯地平治疗高血压合并冠心病的效果对血管内皮功能及颈动脉内膜中层厚度(IMT)的影响。方法选取高血压合并冠心病患者122例,采取随机数字表法分为观察组(n=61)和对照组(n=61),观察组给予吲达帕胺联合苯磺酸左旋氨氯地平治疗,对照组仅给予苯磺酸左旋氨氯地平治疗,两组疗程均为3个月。疗程结束后对比两组血压控制情况,检测血管内皮功能指标及颈动脉内膜中层厚度(IMT)的改善情况。结果疗程结束后观察组舒张压(SBP)与收缩压(DBP)值改善水平明显优于对照组(P<0.05);疗程结束后观察组肱动脉内径(Do)、血流介导的血管舒张反应(FMD)、硝酸甘油介导的血管舒张反应(NMD)与IMT改善水平明显优于对照组,差异有统计学意义(P<0.05)。结论吲达帕胺联合苯磺酸左旋氨氯地平治疗高血压合并冠心病相比于单一使用苯磺酸左旋氨氯地平具有更好的临床效果,可有效改善血管内皮功能,降低IMT。
Objective To study the effects of indapamide combined with levamlodipine besylate in the treatment of hypertension with coronary heart disease and its effects on vascular endothelial function and carotid intima-media thickness(IMT).Methods A total of 122 patients with hypertension and coronary heart disease admitted to our hospital were enrolled.The patients were randomly divided into observation group(n=61)and control group(n=61).The observation group was treated with indapamide and levamlodipine besylate.The control group was treated with levamlodipine besylate.The course of treatment was 3 months.After the end of the treatment,the blood pressure control was compared between the two groups.The improvement of vascular endothelial function index and carotid intima-media thickness(IMT)was examined.Results After the end of the treatment,the improvement of diastolic blood pressure(SBP)and systolic blood pressure(DBP)in the observation group was significantly better than that in the control group(P<0.05).At the end of the treatment,the radial diameter(Do),blood flow-mediated vasodilation(FMD),and nitroglycerin-mediated NMD and IMT improvement in the observation group were significantly better than those in the control group(P<0.05),the difference was statistically significant(P<0.05).Conclusion Indapamide combined with levamlodipine besylate in the treatment of hypertension with coronary heart disease has better clinical effect than single use of levamlodipine besylate,which can effectively improve endothelial function and reduce IMT.
作者
张敏
康丹丹
赵志刚
Zhang Min;Kang Dandan;Zhao Zhigang(Asculocardiology Deparment Ward One,Hebi City People's Hospital,Hebi 458000,China)
出处
《哈尔滨医药》
2020年第4期301-303,共3页
Harbin Medical Journal
基金
2018年河南省医学科技攻关计划联合共建项目(2018021001)。
